Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239
November 04, 2021 06:00 ET
|
Aptose Biosciences, Inc.
HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients Aptose to host conference call and webcast today at 9:00 am ET SAN DIEGO and TORONTO and SEOUL, South Korea, Nov. 04,...
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
October 26, 2021 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Expands Senior Leadership Team
October 25, 2021 08:00 ET
|
Aptose Biosciences, Inc.
Janet Clennett, CPA, appointed Vice President, Finance Roger Davies, B.Sc., M. Phil, joins as Vice President, Operations SAN DIEGO and TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences...
Aptose to Present at September Investor Conferences
August 30, 2021 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Second Quarter 2021
August 03, 2021 16:01 ET
|
Aptose Biosciences, Inc.
- Conference call and webcast at 5:00 pm EDT today - - Luxeptinib Phase 1a/b studies in AML and B cell malignancies fully enrolled at 750 mg dose - - APTO-253 Phase 1a/b study in AML / MDS treating...
Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
July 20, 2021 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Presents Highlights from EHA During Corporate Update Event
June 11, 2021 07:55 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
June 01, 2021 16:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose to Hold Corporate Update Friday, June 11th
May 27, 2021 07:30 ET
|
Aptose Biosciences, Inc.
Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at EHA2021 Virtual...
Aptose to Present at Upcoming Investor Conferences
May 12, 2021 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...